DRREDDY.NS - Dr. Reddy's Laboratories Limited
| Previous Close | 2,545.40 |
| Open | 0.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 2,524.00 - 2,560.65 |
| 52 Week Range | 1,872.95 - 2,964.00 |
| Volume | 572,660 |
| Avg. Volume | 631,804 |
| Market Cap | 421.077B |
| Beta (3Y Monthly) | 0.16 |
| PE Ratio (TTM) | 20.24 |
| EPS (TTM) | 125.54 |
| Earnings Date | May 10, 2018 - May 14, 2018 |
| Forward Dividend & Yield | 20.00 (0.79%) |
| Ex-Dividend Date | 2019-07-15 |
| 1y Target Est | 2,587.45 |
- Simply Wall St.
Does Dr. Reddy's Laboratories (NSE:DRREDDY) Deserve A Spot On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Vigabatrin Powder for Oral Solution, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Vigabatrin Powder for Oral Solution, USP in 500 mg per packet, a therapeutic equivalent generic version of Sabril® Powder for Oral Solution, USP, approved by the U.S.
- Business Wire
Dr. Reddy's Laboratories announces the launch of Versavo® (bevacizumab biosimilar) in India
Dr. Reddy’s Laboratories Ltd. announced today that it has launched Versavo® , a biosimilar of Roche’s Avastin® in India, indicated for the treatment of several types of cancers .
- Business Wire
Exelixis and Aurigene Enter Into Exclusive Collaboration, Option and License Agreement to Discover and Develop Novel Therapies for Cancer
Exelixis, Inc. (EXEL) today announced that it has entered into an exclusive collaboration, option and license agreement with Aurigene Discovery Technologies Limited (Aurigene), the India-based discovery biotechnology company focused on oncology and inflammatory disorders. The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene, which has developed a focused approach to drug discovery that targets differentiated first-in-class and best-in-class opportunities with unique mechanisms of action. The deal is part of Exelixis’ ongoing strategy to build an innovative pipeline behind the company’s internally discovered, commercially available therapies, including its flagship product, CABOMETYX® (cabozantinib).
- Simply Wall St.
What Does Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) P/E Ratio Tell You?
This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios...
- Business Wire
Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica® Capsules approved by the U.S.
- Business Wire
Dr. Reddy’s Q1 FY20 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the quarter ended June 30, 2019 under International Financial Reporting Standards .
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Ramelteon Tablets, in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Ramelteon Tablets, 8 mg, a therapeutically equivalent generic version of Rozerem® Tablets, approved by the U.S.
- Business Wire
Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA™ to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Limited , announces the closure of the transaction with Upsher-Smith Laboratories, LLC , pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 , as amended.
- Business Wire
Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Fexofenadine HCl 60 mg and Pseudoephedrine HCl 120 mg Extended-Release Tablets, USP, an over-the-counter store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S.
- Reuters
Indivior loses appeal to block generic Suboxone opioid treatments
The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents. Suboxone film is applied below a patient's tongue, where it dissolves to release two active ingredients, buprenorphine and naloxone.
- Reuters
UPDATE 1-Indivior loses appeal to block generic Suboxone opioid treatments
A divided federal appeals court on Friday ruled against Indivior Plc in its bid to stop Dr. Reddy's Laboratories Ltd and Alvogen from selling generic versions of its opioid addiction treatment Suboxone film that infringed its patents. The U.S. Federal Circuit Court of Appeals in Washington, which oversees many intellectual property cases, upheld lower court rulings that Dr. Reddy's did not infringe two Indivior patents related to Suboxone, and Alvogen did not infringe one of those patents.
- Simply Wall St.
Read This Before Considering Dr. Reddy's Laboratories Limited (NSE:DRREDDY) For Its Upcoming 0.8% Dividend
Dr. Reddy's Laboratories Limited (NSE:DRREDDY) is about to trade ex-dividend in the next 2 days. Investors can...
- Business Wire
Dr. Reddy's to release Q1 FY 20 results on July 29, 2019
Earnings call slated for July 29, 6:30 PM IST / 9:00 AM EDT
- Business Wire
Dr. Reddy’s Announces the Launch of the Over-the-counter Store Brand Equivalent of Mucinex® D Extended Release Tablets in Two Strengths in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of an over-the-counter store-brand equivalent of Mucinex® D Extended Release Tablets in two strengths—Guaifenesin 600 mg and Pseudoephedrine HCl 60 mg, and Guaifenesin 1200 mg and Pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S.
- Business Wire
Dr. Reddy's Laboratories Announces First-to-market Launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Carboprost Tromethamine Injection USP, 250 mcg/mL Single-dose Vial, a therapeutic equivalent generic version of Hemabate® injection, 250 mcg/mL, approved by the U.S.
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Tobramycin Inhalation Solution, USP in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of TOBI® Inhalation Solution, approved by the U.S.
- Simply Wall St.
Dr. Reddy's Laboratories Limited (NSE:DRREDDY): What We Can Expect From This Growth Stock
Looking at Dr. Reddy's Laboratories Limited's (NSE:DRREDDY) earnings update on 31 March 2019, it seems that analyst...
- Simply Wall St.
Dr. Reddy's Laboratories Limited (NSE:DRREDDY): What Does The Future Look Like?
As Dr. Reddy's Laboratories Limited (NSE:DRREDDY) released its earnings announcement on 31 March 2019, it seems that...
- Business Wire
Dr. Reddy's Laboratories Announces the Launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules, a therapeutic equivalent generic version of Vitamin K1 Injectable Emulsion USP, 10 mg/ml, approved by the U.S.
- Business Wire
Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Limited announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC , pursuant to which Dr.
- Business Wire
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy’s Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis
Dr. Reddy’s Laboratories Ltd. announced positive topline results from its Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis.
- Business Wire
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy’s Laboratories Limited today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended March 31, 2019 was filed with the United States Securities and Exchange Commission on June 3, 2019.
- Business Wire
Dr. Reddy's Laboratories Announces the Re-Launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market
Dr. Reddy’s Laboratories Ltd. today announced the re-launch of Zenatane® , 10 mg, 20 mg, 30 mg and 40 mg, a therapeutic equivalent generic version of Accutane®, approved by the U.S.
- Business Wire
Dr. Reddy’s Q4 & FY19 Financial Results
Dr. Reddy’s Laboratories Ltd. today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2019 under International Financial Reporting Standards .
